Hear from A/Prof. Kerry Hitos, Director of the Westmead Research Centre for Evaluation of Surgical Outcomes, University of Sydney, Westmead Hospital.
A/Prof. Kerry Hitos describes why Australian researchers have excellent reputations.
An individualised patient-centered approach for assessing VTE risk in medical patients is recommended by A/Prof. Kerry Hitos.
A/Prof. Kerry Hitos reviews the new ACSQH Clinical Care Standards and recommends practices that could see 100% of patients appropriately prophylaxed against VTE.
VTE = venous thromboembolism.
Date of preparation: March 2019. SM_SAN980. SAANZ.ENO.19.01.0069
*Clexane Safety Lock as an automatic safety lock system.
Further information is available on request from Sanofi.
.png?h=50&la=en&hash=87F9222B98BD661558CA9E98EC0CB1A085358426)
PBS Information: CLEXANE®. General Benefit Antithrombotic agent. Refer to PBS schedule for full information. CLEXANE® FORTE. This product is not listed on the PBS. CLEXANE® with Automatic Safety Lock System. This product is not listed on the PBS
Please review Product Information before prescribing Clexane. Full Product Information is available by calling 1800 818 806 or by clicking here.
sanofi-aventis australia pty ltd training as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. ®Clexane is a registered trademark of sanofi-aventis.
Receive future issues of Anticoagulation Matters, compiled specifically for you.
Access patient information and resources on VTE and Clexane®.